Celsion denies plans to sell BPH (benign prostatic hyperplasia) business
This article was originally published in Clinica
Celsion, formerly Cheung Laboratories, says it has no intention of selling its benign prostatic hyperplasia (BPH) business "at this time". The announcement was made in response to an unsolicited offer, which the Celsion management found "did not reflect a true and fair value" of the business.
You may also be interested in...
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.